cas 392726-69-1|| where to buy N-(5-Bromo-2-(trifluoromethoxy)phenyl)acetamide

Nom du produit:N-(5-Bromo-2-(trifluoromethoxy)phenyl)acetamide

IUPAC Name:N-[5-bromo-2-(trifluoromethoxy)phenyl]acetamide

Unité d'emballage	Stock disponible	Prix($)
CM183707-1g	in stock	źƄ
CM183707-5g	in stock	ǊưȎ
CM183707-10g	in stock	ȎĽź

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 392726-69-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:392726-69-1; Formule moléculaire:C9H7BrF3NO2; Point de fusion:-; Code SMILES:CC(NC1=CC(Br)=CC=C1OC(F)(F)F)=O; Densité:

: Numéro de catalogue:CM183707; Poids moléculaire:298.06; Point d'ébullition:; N° Mdl:MFCD02317366; Stockage:Store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Onvansertib; Polo-like kinase 1 (PLK1) is a key regulator of the cell-cycle progression found in human cancers, and a potential therapeutic target for oncology drug development. The recent journal Clinical Cancer Research details the Phase 1b Study of Onvansertib in combination with chemotherapy+bevacizumab treatment for patients with patients with KRAS-mutated metastatic colorectal cancer (mCRC).
Cardiff Oncology’s novel inhibitor, Onvansertib effectively targets PLK1, that prevents from tumor cell growth. It aids restore DNA damage and promote the efficacy of the standard of care therapy in a number of indications.